BPC 157 FDA Approval Unlikely Due to Patent Economics Stefano M. Sinicropi, MD posted on the topic LinkedIn The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban Ars Technica FDA's Overreach on Compounded Peptides BPC 157 Weight Loss: Evidence & Safety